ArticleScientific reports2026
RSM optimization of Tetracycline-loaded PLGA nanoparticles in chitosan/HPMC hydrogels for sustained antibacterial delivery.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Mechanism and Application of Traditional Chinese Medicine Nano-Formulations in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising prevalence of antimicrobial resistance and biofilm infections requires innovative drug delivery systems for sustained local antibiotic release with minimal systemic exposure. This study reports the development and characterization of novel nanocomposite hydrogels combining chitosan (CS) and hydroxypropyl methylcellulose (HPMC) matrices embedded with optimized tetracycline (TTC)-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) for sustained antibacterial delivery. Using a double emulsion solvent evaporation technique, TTC-loaded PLGA NPs were fabricated, and their physicochemical properties-including particle size, encapsulation efficiency % (EE), and drug loading % (DL)-were optimized via Response Surface Methodology (RSM) based on a Box-Behnken design. Optimized NPs exhibited a size of ~ 229 nm, EE of 57.2%, and DL of 0.72%. Fourier transform infrared (FTIR) spectroscopy and scanning electron microscopy (SEM) confirmed successful encapsulation and spherical morphology of the NPs. In vitro release profiles revealed biphasic TTC release from free drug-loaded CS/HPMC hydrogels (95% within 6 h; ~98% by 24 h), whereas NP-loaded nanocomposites exhibited sustained kinetics (initial burst of ~ 48% in 6 h; ~60% at 24 h). Disk diffusion assays confirmed potent antibacterial effects of nanocomposite hydrogels against both E. coli and S. aureus, superior to free drug formulations. Incorporation of optimized NPs into a CS/HPMC hydrogel matrix yielded nanocomposite hydrogels with enhanced mechanical integrity, controlled swelling behavior, and reduced degradation rates compared to hydrogels with free drug or without NPs. This platform leverages hydrogel-NP synergy for prolonged TTC delivery in localized infection management and resistance mitigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.